Call for Papers: Current Challenges in Comorbidities with Addiction

The Canadian Journal of Addiction is pleased to announce a Call for Papers for a Special Issue: “Current Challenges in Comorbidities with Addiction” for publication in Fall/Winter 2021.

The interface between substance-related and addictive disorders with medical illness and psychiatric disorders is complex and challenging. For those presenting to treatment, comorbidity is the norm rather than the exception. Compared to persons with a medical illness or psychiatric disorder alone, persons with substance-related and addictive disorder comorbidity typically have greater illness severity and overall worse longitudinal course relating to more difficult to treat illnesses, decreased treatment retention, increased risk of relapse to both entities, greater psychosocial barriers, worse medication adherence, higher rates of violence and suicide, and higher utilization of acute care services. Broad dissemination of current research and clinical perspectives in the management of persons with comorbidity is critically important to inform clinicians, researchers, policy makers, community members, and other stakeholders.

This Special Issue will focus on current research, challenges, and clinical implications of substance-related and addictive disorders with medical and/or psychiatric comorbidity.

Specific topics of interest include:

- Substance-related and addictive disorder comorbidity with major psychiatric disorders (e.g.: psychotic disorders, mood disorders, anxiety disorders, PTSD, ADHD, eating disorders, personality disorders, etc).
- Substance-related and addictive disorder comorbidity with chronic pain.
- Substance-related and addictive disorder comorbidity with major medical disorders (e.g.: HIV, hepatitis, cardiovascular disease, endocrine illness, etc).
- Substance use disorders comorbid with behavioural addictions.

We encourage submission of original research reports, brief reports, systematic reviews, and narrative reviews in this area (see link to authors’ guidelines below). Short expert commentaries will also be considered with prior approval of the Special Issue Editor. Case reports will not be considered for this issue.

All submissions will undergo normal peer review. All manuscripts must be submitted at www.editorialmanager.com/cja. Submission deadline for consideration for this special issue is March 31, 2021.

Questions or inquiries about the special issue can be directed to the Special Issue Editor, Dr. David Crockford (david.crockford@ahs.ca) or CJA Editor-inChief, Nady el-Guebaly, CM, MD (Nady.El-guebaly@albertahealthservices.ca).

For authors’ guidelines, information on the peer review process, and manuscript submissions, please visit www.editorialmanager.com/cja.